

ASX ANNOUNCEMENT

30 November 2023

CEO Update on Financial Results



Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to provide a recording of Chief Executive Officer Paul Long providing commentary on the Company's Half Year financial results, which have been released to market this morning.

As part of the video update, Mr. Long discusses LGP's accelerating growth over the period, which saw the Company deliver a 40% increase in revenue to \$12.8m during the half, as well as positive EBITDA of \$700,000.

In addition, Mr. Long will also provide a further update on Little Green Pharma's activities in the strategic and highly lucrative European medicinal cannabis markets, including the significant demand experienced in regions such as Germany and Poland. LGP has also had a strong involvement with a French Government-backed trial which is anticipated to pave the way for the product within French healthcare system.

A link to the video can be found here: <https://investlittlegreenpharma.com/site/about/ceo-update-on-financial-results>

ENDS
BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer

Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp